GlassScriptPhysician profile
Eric S Rachal
NPI 1538866793
$9,036.91
in general payments reported to CMS, 2019-2025
25 companies · $3,252 in 2025
The $3,252 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,424 · 2024: $3,361 · 2025: $3,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,952 · Education: $84.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,952.46 |
| Education | $84.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,414.19 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,241.85 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $908.97 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $844.38 | 2023-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $691.03 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $582.15 | 2023-2025 | Auvelity |
| Corium, LLC | $511.20 | 2023-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $440.72 | 2023-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $380.61 | 2023-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $344.01 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Supernus Pharmaceuticals, INC. | $335.84 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $291.47 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $194.95 | 2023-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $173.42 | 2023-2024 | Jornay Pm |
| Alexion Pharmaceuticals, INC. | $130.20 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $103.90 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $101.80 | 2023-2024 | Xelstrym, Secuado |
| Sage Therapeutics, LLC | $62.83 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $58.00 | 2024 | Quviviq |
| Indivior INC. | $57.37 | 2024 | Perseris |
| Tris Pharma INC | $51.46 | 2023 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $38.68 | 2025 | Jornay Pm |
| Bioxcel Therapeutics, INC. | $31.97 | 2023 | Igalmi |
| Merck Sharp & Dohme LLC | $27.73 | 2023 | Belsomra |
| Noven Pharmaceuticals, INC. | $18.18 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Rachal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.